However, when looking at the tauopathy continuum, the CTE stages, including late stage CTE IV, fell below the increases seen for FTLD-MAPT levels in multiple modules and cell subtype abundance, especially with astrocytes, suggesting that FTLD-MAPT has a more prominent glial component. This evidence concerns the gene MAPT and tauopathy.